-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2022H1, the sales scale of terminal proprietary Chinese medicines in public hospitals in key cities exceeded 15 billion yuan, and Beijing led the sales scale; Drugs for cardiovascular and cerebrovascular diseases were the first best-selling category, and dermatology drugs and qi and blood supplements all increased by more than 15%.
Among the TOP20 products, Jinshuibao tablets once again ranked first, and 12 products were exclusive varieties; Among the top 20 brands, Zuoli, Yangtze River, Peking University Weixin.
.
.
5 brands showed impressive
gains.
Among the TOP20 products, Jinshuibao tablets once again ranked first, and 12 products were exclusive varieties; Among the top 20 brands, Zuoli, Yangtze River, Peking University Weixin.
.
.
5 brands showed impressive
gains.
01.
Cardiovascular and cerebrovascular disease drugs lead the three major categories up more than 10%
Cardiovascular and cerebrovascular disease drugs lead the three major categories up more than 10%
According to the latest data from Minai.
com, affected by the rebound of the domestic epidemic and the promotion of procurement with volume, the sales scale of terminal proprietary Chinese medicines in public hospitals in key cities in the first half of 2022 exceeded 15 billion yuan, an increase of only 0.
3%
year-on-year.
com, affected by the rebound of the domestic epidemic and the promotion of procurement with volume, the sales scale of terminal proprietary Chinese medicines in public hospitals in key cities in the first half of 2022 exceeded 15 billion yuan, an increase of only 0.
3%
year-on-year.
Among them, the sales scale in the first quarter increased by 7.
05% compared with the same period last year, and the second quarter decreased by 5.
82%
year-on-year.
05% compared with the same period last year, and the second quarter decreased by 5.
82%
year-on-year.
Sales of proprietary Chinese medicines in public hospitals in key cities (100 million yuan)
From the perspective of urban pattern, Beijing, Guangzhou and Chongqing ranked the top three in terms of sales scale, of which the sales scale of terminal proprietary Chinese medicines in Beijing public hospitals exceeded 5 billion yuan, far ahead of other cities; Seven cities achieved positive sales growth, including Ningbo, Hangzhou, Chongqing, Wuhu, Nanjing, Qingdao and Jinan
.
.
Among the 13 major categories of proprietary Chinese medicines, drugs for cardiovascular and cerebrovascular diseases are the best-selling category, with a market share of nearly 30%; The market share of drugs for tumor diseases, skeletal and muscular diseases, and drugs for respiratory diseases exceeded 10%; The sales performance of three categories, namely dermatology drugs, qi and blood supplementation drugs, and neurological disease drugs, increased by 16.
76%, 15.
65% and 10.
30% year-on-year, respectively
.
76%, 15.
65% and 10.
30% year-on-year, respectively
.
2022H1 pattern of proprietary Chinese medicines in public hospitals in key cities
02.
Top 20 proprietary Chinese medicines released 12 exclusive proprietary Chinese medicines are eye-catching
Top 20 proprietary Chinese medicines released 12 exclusive proprietary Chinese medicines are eye-catching
Among the TOP20 proprietary Chinese medicine products, Jinshuibao tablets once again ranked first, Bailing capsules and Suhuang cough suppressant capsules ranked second and third respectively; The sales scale of 16 products exceeded 100 million yuan, of which Jinshuibao tablets, Bailing capsules and Suhuang cough capsules all exceeded 200 million yuan
.
.
2022H1 Top 20 proprietary Chinese medicine products in public hospitals in key cities
The 20 products involve 8 treatment categories, including as many as 7 products on the list for cardiovascular and cerebrovascular diseases, 4 products for oncological diseases, and 3 products for urological diseases
.
.
The 12 products are exclusive proprietary Chinese medicines, including Suhuang cough suppressant capsules and Lanqin oral liquid from Yangzijiang Pharmaceutical Group, Pediatric Soy Qingheat Granules from Jichuan Pharmaceutical, Tasly's Compound Danshen Drop Pills, Bailing Capsules from East China and the United States, Musk Baoxin Pills from Hutchison Pharmaceutical, and Blood Lipid Kang Capsules from Peking University Weixin
.
.
03, 5 brands rose by more than 10% Zuoli, Yangtze River, Peking University Weixin.
.
.
.
.
Among the top 20 Chinese patent pharmaceutical brands, Jimin's credible Jinshuibao tablets ranked first, Sino-US East China's Bailing capsules ranked second, Yangtze River Pharmaceutical Group's Suhuang cough capsules and Lanqin oral liquid ranked third and fourth respectively, and Jichuan Pharmaceutical's Pediatric Qiaoqiao Qingheat Granules ranked fifth
.
.
2022H1 Top 20 proprietary Chinese medicine brands in public hospitals in key cities
From the perspective of sales changes, 12 of the 20 brands achieved positive growth, and 5 brands increased by more than 10%, including Suhuang cough capsules of Yangtze River Pharmaceutical Group, Musk Baoxin Pills of Hehuang Pharmaceutical, Tongteng injection of Nanjing Shenghe Pharmaceutical, Blood Lipid Kang capsules of Peking University Weixin, and Wuling capsules
of Zuoli Pharmaceutical.
Except for the clearance vine injection, the rest are exclusive varieties
.
of Zuoli Pharmaceutical.
Except for the clearance vine injection, the rest are exclusive varieties
.
Zuoli Pharmaceutical's Wuling capsule is made of a single ingredient Wuling bacteria, which has the effect of tonifying the kidney and strengthening the brain, nourishing the mind and calming the mind, suitable for neurasthenic heart and kidney without delivery, and is a national medical insurance class A, national basic drug, OTC class A variety
.
According to data from Minai.
com, the terminal sales scale of Wuling capsules in public hospitals in key cities has continued to rise in recent years, with a year-on-year increase of 13.
63% in 2021 and 22.
55%
in 2022H1 compared with the same period last year.
.
According to data from Minai.
com, the terminal sales scale of Wuling capsules in public hospitals in key cities has continued to rise in recent years, with a year-on-year increase of 13.
63% in 2021 and 22.
55%
in 2022H1 compared with the same period last year.
Yangzijiang Pharmaceutical Group's Suhuang cough capsule has the effect of draining the lungs and relieving cough and pharynx, and is used for cough and itching caused by wind and evil offenders' lungs and lung qi loss, and is a national medical insurance class B and national basic drug
.
In 2021 and the first half of 2022, the terminal sales scale of Suhuang cough capsules in public hospitals in key cities increased by 24.
99% and 22.
26%
year-on-year, respectively.
.
In 2021 and the first half of 2022, the terminal sales scale of Suhuang cough capsules in public hospitals in key cities increased by 24.
99% and 22.
26%
year-on-year, respectively.
Peking University Weixin's Blood Lipid Kang Capsules under Luye Pharmaceutical is a proprietary traditional Chinese medicine extracted from red yeast rice, and the indication is hypercholesterolemia
.
The product has been verified by comprehensive evidence-based medical clinical research, and the lipid-lowering effect has been internationally recognized
.
In January 2019, AstraZeneca signed an agreement with Luye Pharmaceutical to obtain the exclusive promotion right of Lipidkang capsules in Chinese mainland, which is also the first time that a large multinational pharmaceutical company has promoted proprietary Chinese medicine products
in China.
With the help of AstraZeneca, the Lipidicon capsule market has continued to expand in recent years, with growth rates of 32.
71%, 22.
62% and 16.
52%
in 2020-2022H1, respectively.
.
The product has been verified by comprehensive evidence-based medical clinical research, and the lipid-lowering effect has been internationally recognized
.
In January 2019, AstraZeneca signed an agreement with Luye Pharmaceutical to obtain the exclusive promotion right of Lipidkang capsules in Chinese mainland, which is also the first time that a large multinational pharmaceutical company has promoted proprietary Chinese medicine products
in China.
With the help of AstraZeneca, the Lipidicon capsule market has continued to expand in recent years, with growth rates of 32.
71%, 22.
62% and 16.
52%
in 2020-2022H1, respectively.
Source: Minainet database
Note: The competition pattern of proprietary Chinese medicine terminals in public hospitals in key cities of Minai.
com is based on the procurement data of all public hospitals in 16 key cities including Beijing, Guangzhou and Nanjing, and the sample hospital database of sample cities that continuously monitors all categories of proprietary Chinese medicines.
The above sales are calculated
based on the average retail price of the product at the terminal.
com is based on the procurement data of all public hospitals in 16 key cities including Beijing, Guangzhou and Nanjing, and the sample hospital database of sample cities that continuously monitors all categories of proprietary Chinese medicines.
The above sales are calculated
based on the average retail price of the product at the terminal.
